Recommended in Urology

  • Clinical Essentials from J Clin Oncol
  • 1 comment

Advanced RCC: adjuvant pazopanib 600 mg fails to show benefit

PROTECT phase 3 study shows DFS advantage for 800-mg dose.

Read more
  • Univadis
  • 1 comment

ESMO 2017: Ramucirumab plus docetaxel slightly improves PFS in urothelial cancer

Read more
  • Clinical Essentials from Lancet
  • 1 comment

Refractory urothelial cancer: add-on ramucirumab boosts PFS

Read more
  • Univadis
  • 1 comment

ESMO 2017: Docetaxel and abiraterone acetate plus prednisolone equally improved survival in patients with high-risk prostate cancer: first results from the STAMPEDE trial

Read more
  • Clinical Essentials from Eur Urol
  • 1 comment
  • FULLTEXT

cN1 prostate cancer: localized add-ons to ADT boost survival

Read more
  • Clinical Essentials from Clin Genitourin Cancer
  • 1 comment

Intermediate-risk prostate cancer: which treatment is best?

Read more
  • Univadis
  • 1 comment

ASCO 2017 - Metastatic castration-resistant prostate cancer: indoximod after sipuleucel-T boosts PFSl in phase 2 trial

Read more
  • Univadis
  • 1 comment

ASCO 2017 - Urothelial cancer: pembrolizumab tops 2nd-line chemotherapy

Read more
  • Univadis
  • 1 comment

ASCO 2017 - High-intensity ctDNA assay promising in metastatic breast, lung, and prostate cancers

Read more

Professional Essentials

  • Patients Will Be Asking

Are my microbes making me fat?

Read more
  • US Professional News
  • FULLTEXT

Job market for residents a "feeding frenzy"

Read more
  • US Professional News
  • FULLTEXT

Physician gave office manager 39 drugs

Read more
  • US Professional News
  • FULLTEXT

Insurers targeted for opioid practices

Read more
  • US Professional News
  • FULLTEXT

Whistleblowing neurosurgeon gets $17.5 million

Read more
  • US Professional News
  • FULLTEXT

Is your EHR vendor keeping up?

Read more
View more

New in Urology

  • Clinical Essentials from Radiat Oncol
  • 1 comment

Localized prostate cancer: PSA nadir 0.06 ng/mL predicts relapse

T-stage and Gleason score also predict BCR after definitive therapy.

Read more
  • Clinical Essentials from PLoS One
  • no comment
  • FULLTEXT

Fluoroquinolones and prolonged GI perforation risk

Higher adjusted perforation risks even months after a course of antibiotics.

Read more
  • Clinical Essentials from Ann Intern Med
  • no comment

Prostate cancer: PSA screening does reduce mortality

A new look at old data from ERSPC and PLCO.

Read more
  • Clinical Essentials from Brachytherapy
  • 1 comment

Prostate cancer: early prediction of PSA relapse after LDR-BT

PSA nadir, 4-8wkPSA, and some pretreatment factors predict biochemical relapse.

Read more
  • Clinical Essentials from Prostate Int
  • 1 comment
  • FULLTEXT

Poor glycemic control may reduce prostate-specific antigen in men

Poor glycemic control of type 2 diabetes was associated with lower serum PSA levels and smaller prostate volumes.

Read more
  • Clinical Essentials from Br J Can
  • no comment

Prostate cancer: ADT raises risk for cardiovascular disease

Study shows elevated risks for heart failure, arrhythmias, and conduction disorders.

Read more
  • Clinical Essentials from US Food and Drug Administration
  • 1 comment
  • FULLTEXT

Vabomere wins FDA approval for complicated UTI

The antibacterial is a combination of meropenem and vaborbactam.

Read more
Genitourinary Cancer Vitals for August 2017
  • Vitals
  • 1 comment

Genitourinary Cancer Vitals for August 2017

Bisphosphonates and bone loss with ADT | Caution with long-term ADT | Cabazitaxel vs docetaxal in prostate cancer.

Read more
  • Clinical Essentials from J Clin Oncol
  • 1 comment

Study nixes link between ADT, Alzheimer’s disease in older men

Data from a cohort study of 1.2 million elderly prostate cancer survivors.

Read more
Kidney Disease Vitals for August 2017
  • Vitals
  • 1 comment

Kidney Disease Vitals for August 2017

Serious infection risk with steroids in IgA nephropathy | Post-GU cancer renal transplant: how long to wait? | PPIs linked to CKD risk.

Read more
  • Clinical Essentials from J Urol
  • 1 comment

Radical prostatectomy: can PSA testing be stopped after 20 y?

Long-term study analyzed probability and risk factors for BCR.

Read more
  • Clinical Essentials from J Urol
  • 1 comment

mCRPC: is enzalutamide effective in patients >75 y?

Post hoc analysis of TERRAIN study.

Read more
  • Clinical Essentials from Anesth Analg
  • no comment

Sleep apnea: STOP-Bang score aids surgical risk stratification

A meta-analysis evaluating use of the STOP-Bang score for predicting surgical risk.

Read more
  • Clinical Essentials from BJU Int
  • 1 comment

mpMRI tops biopsy for identifying aggressive apical prostate cancer

MRI can be useful for planning the extent of apical preservation during prostatectomy

Read more